Transform lives through genetic discovery.
1001 - 5000
π° Post-IPO Debt on 2020-05
November 6
Transform lives through genetic discovery.
1001 - 5000
π° Post-IPO Debt on 2020-05
β’ Develop a global medical society engagement strategy for BioMarin's portfolio of existing and pipeline products. β’ Ensure excellence in additional society opportunities across the global organization. β’ Partner closely with regional and country colleagues. β’ Maintain a focus on key strategic markets and assets.
November 6
1001 - 5000
Lead medical society engagement strategy for BioMarin's portfolio in genetics.
November 6
10,000+
Lead data management department for Thermo Fisher Scientific's strategic development plans.
November 6
201 - 500
IGM develops autoimmunity medicines; seeking a Sr. Director of Clinical Development.
πΊπΈ United States β Remote
π΅ $235k - $270k / year
π° $200M Post-IPO Equity on 2022-03
β° Full Time
π Senior
π Director
November 6
501 - 1000
Oversees biometric services at Lexitas, a leading ophthalmic product development firm.
πΊπΈ United States β Remote
π΅ $185k - $205k / year
π° Debt Financing on 2016-09
β° Full Time
π Senior
π Director